Co-transplantation of stromal cells interferes with the rejection of allogeneic islet grafts

Annals of the New York Academy of Sciences
Stella JacobsonMalin Flodström-Tullberg

Abstract

Side effects associated with current immunosuppressive therapy complicate the use of islet transplantation as a treatment for type 1 diabetes. Multipotent mesenchymal stromal cells (MSCs) have demonstrated immunomodulatory activity. The purpose of this study was to investigate whether a murine stromal cell line affects graft rejection in a fully major histocompatibility complex (MHC)-mismatched islet transplant model. We show that stromal cells have an inhibitory effect on T cell proliferation in vitro, and that they slow down the rejection of allogeneic islets. These findings indicate a possibility to use MSCs as a treatment to prolong the survival of islet grafts.

References

Feb 1, 1984·Journal of Cellular Physiology·D ZiporiZ Malik
Feb 2, 2002·Experimental Hematology·Amelia BartholomewRonald Hoffman
Dec 14, 2004·Immunity·Mattias SvenssonPaul M Kaye
Nov 10, 2005·Annals of Medicine·H Kalervo Väänänen
Apr 25, 2006·Experimental Cell Research·Ida Rasmusson
Aug 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Simon JonesFrancesco Dazzi

❮ Previous
Next ❯

Citations

Jul 13, 2011·Current Diabetes Reports·Danielle J Borg, Ezio Bonifacio
Jul 9, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alejandro Gómez-AristizábalJohn E Davies
May 10, 2012·Ageing Research Reviews·Yan PengXiaobing Fu
Aug 26, 2018·Biotechnology and Bioengineering·Marcos Perez-BasterrecheaAlvaro J Obaya
Jul 14, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anh Thu Nguyen HoangMattias Svensson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.